CASTLE BIOSCIENCES INC
CSTLNASDAQTrading Snapshot
- Day Range
- $597.91 – $604.58
- 52-Week Range
- $17.72 – $44.28
- Volume
- $2.42B
- Avg Volume
- $1.72B
- Shares Outstanding
- 30.5M
- Next Earnings
- Oct 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $344M
- Last Q Revenue
- $104M
- P/E Ratio
- -54.5
- P/S Ratio
- 3.1x
- EPS (TTM)
- $-0.64
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −2.9%
Why Investors Own CSTL
- ✓High-growth profile — revenue up +38.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 58% gross margin and 17% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CASTLE BIOSCIENCES INC
CSTL
StockOtter · stockotter.spaceAbout CASTLE BIOSCIENCES INC
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
CASTLE BIOSCIENCES INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift CSTL price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
CASTLE BIOSCIENCES INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.